PFE · News · 20261104N

Strategic Portfolio Refocus

PFIZER INC · 2026-11-04 · Importance 46 · Surprise 42

United Therapeutics agreed to pay Pfizer subsidiary Arena Pharmaceuticals $525 million upfront to eliminate all royalty obligations under its exclusive license agreement for ralinepag. The buyout removes a double-digit royalty on all formulations, including oral and inhaled versions, and applies to a drug awaiting FDA review for pulmonary arterial hypertension. United Therapeutics remains responsible for contingent regulatory milestone payments totaling $400 million.